THC Biomed Intl Ltd. produces and sells medical marijuana in Canada.
+ 2 more risks
Adequate balance sheet with weak fundamentals.
Share Price & News
How has THC Biomed Intl's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: THC's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: THC exceeded the Canadian Pharmaceuticals industry which returned -60.7% over the past year.
Return vs Market: THC underperformed the Canadian Market which returned -14.5% over the past year.
Price Volatility Vs. Market
How volatile is THC Biomed Intl's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StDoes Market Volatility Impact THC Biomed Intl Ltd.'s (CSE:THC) Share Price?
2 months ago | Simply Wall StHow Much Are THC Biomed Intl Ltd. (CSE:THC) Insiders Spending On Buying Shares?
3 months ago | Simply Wall StDo Institutions Own THC Biomed Intl Ltd. (CSE:THC) Shares?
Is THC Biomed Intl undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate THC's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate THC's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: THC is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: THC is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate THC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: THC is overvalued based on its PB Ratio (1.5x) compared to the CA Pharmaceuticals industry average (1.2x).
How is THC Biomed Intl forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as THC Biomed Intl has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine THC Biomed Intl's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- THC Biomed Intl competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has THC Biomed Intl performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: THC is currently unprofitable.
Growing Profit Margin: THC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: THC is unprofitable, and losses have increased over the past 5 years at a rate of -46.2% per year.
Accelerating Growth: Unable to compare THC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: THC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-23.4%).
Return on Equity
High ROE: THC has a negative Return on Equity (-52.54%), as it is currently unprofitable.
How is THC Biomed Intl's financial position?
Financial Position Analysis
Short Term Liabilities: THC's short term assets (CA$7.3M) exceed its short term liabilities (CA$3.6M).
Long Term Liabilities: THC's short term assets (CA$7.3M) exceed its long term liabilities (CA$1.7M).
Debt to Equity History and Analysis
Debt Level: THC's debt to equity ratio (20.3%) is considered satisfactory.
Reducing Debt: THC's debt to equity ratio has reduced from 3957.1% to 20.3% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: THC has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: THC has less than a year of cash runway if free cash flow continues to reduce at historical rates of 49.2% each year
What is THC Biomed Intl's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate THC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate THC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if THC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if THC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of THC's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Mr. John Miller serves as Chief Executive Officer and President of THC Biomed Intl Ltd. and its Director since June 3, 2014.
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD48.35K) is below average for companies of similar size in the Canadian market ($USD155.78K).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
|President||no data||CA$66.75k||19.68% CA$4.7m|
|Member of Advisory Board||4.83yrs||no data||no data|
|Member of Advisory Board||4.83yrs||no data||no data|
|Independent Director||2.92yrs||CA$6.50k||no data|
|Director||0.17yr||no data||no data|
Experienced Board: THC's board of directors are considered experienced (4.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.2%.
THC Biomed Intl Ltd.'s company bio, employee growth, exchange listings and data sources
- Name: THC Biomed Intl Ltd.
- Ticker: THC
- Exchange: CNSX
- Founded: 2012
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$23.749m
- Shares outstanding: 158.33m
- Website: https://www.thcbiomed.com
Number of Employees
- THC Biomed Intl Ltd.
- 1340 St. Paul Street
- British Columbia
- V1Y 2E1
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|TFHD||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Sep 1988|
|THC||CNSX (Canadian National Stock Exchange)||Yes||Common Shares||CA||CAD||Sep 1988|
|TFHD||DB (Deutsche Boerse AG)||COM NPV||DE||EUR||Apr 2015|
THC Biomed Intl Ltd. produces and sells medical marijuana in Canada. It is also involved in cultivating and researching cannabis. The company was founded in 2012 and is headquartered in Kelowna, Canada.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/05/27 02:39|
|End of Day Share Price||2020/05/26 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.